On January 11, Celltrion and its partner Teva filed 2 new lawsuits against Genentech in a California district court.
On January 11, Celltrion and its partner Teva filed 2 new lawsuits against Genentech in a California district court.
The first complaint seeks a declaratory judgment that 38 patents covering reference trastuzumab (Herceptin) are either invalid, unenforceable, or not infringed by the biosimilars developers’ proposed trastuzumab, currently under consideration by the FDA, which Celltrion and Teva plan to market as Herzuma.
Celltrion and Teva’s complaint states that Genentech has relied on “a complex series of patents from [2] dozen patent families” to forestall biosimilar competition, and that Genentech’s “panoply of vague allegations are simply intended to interfere with Celltrion and Teva’s entry into the market.”
The patents in question include those addressing methods of production, protein purification, the cell culture process, dosage, fixed dosing, methods of treatment, and extending time to disease progression, among others.
Similarly, the second suit seeks a declaratory judgement of non-infringement or invalidity of 37 patents covering reference rituximab (Rituxan), including patents that address combination therapies for B-cell lymphomas, methods for growing mammalian cells in vitro, and treatment of hematologic malignancies using anti-CD20 antibodies, among others.
Celltrion’s rituximab product is also under FDA consideration, and the company plans to eventually market the drug under the brand name Truxima. The product is already approved and marketed in the European Union, and its trastuzumab biosimilar is awaiting final authorization from the European Commission before it, too, begins to make its way to European patients.
This new patent litigation clearing the way for eventual US marketing of the 2 biosimilar products comes as Celltrion prepares to ramp up production capabilities with a new 360,000-liter-capacity plant. By comparison, the company currently owns 2 plants that, when running at their full capability, have capacities of 50,000 liters and 90,000 liters each. The new facility will help to “ensure stable supplies as well as leverage on economy of scale to further lower the prices of its biosimilar drugs,” said Celltrion’s CEO, Jung Jin Seo.
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf
October 25th 2024At the GRx+Biosims conference, FDA Commissioner Robert Califf, MD, stressed the urgent need for data transparency in the global supply chain and the role of collaboration and artificial intelligence in ensuring the resilience of biosimilar and generic drug production.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.